Oberhaching, December 2023
Bendalis GmbH and Inresa Arzneimittel GmbH today announce their new distribution partnership for Somatostatin Lyomark 3 mg known. Through this partnership, Inresa will be the sales and distribution partner for the product.
Inresa has been chosen as the strategic distributor to continue meeting the demand for somatostatin and ensure patient care. Furthermore, Inresa is established with hospitals and known as a reliable partner for its on-time deliveries.
Due to an optimised manufacturing process, Somatostatin will be available in vials from now on, and no longer in ampoules as previously. This change will prevent glass breakages and ensure greater safety in daily use.
In addition, the approval of Somatostatin Lyomark 3 mg transferred from Lyomark Pharma GmbH to the subsidiary Bendalis GmbH.
For deliveries from mid-January onwards, you are welcome to place your order through Inresa Arzneimittel GmbH:
We look forward to working with Inresa and hope that you will continue to remain loyal to Somatostatin Lyomark 3 mg and place the same trust in Inresa.
Bendalis GmbH